← Leaderboards
Robert Fine
Columbia University Health Sciences
$386,788
Attributed
$386,788
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$386,788 · 2
By mechanism
M01$386,788 · 2
Top collaborators
No co-investigators on record.
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Robyn J Barst$2,557,256
- Mary Sano$40,764,266
- Kevan C Herold$39,325,259
- Gary K Schwartz$24,362,901
- Sarah H Lisanby$7,610,671
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchClinical Trial Phase IDosageDrug Adverse EffectDrug Screening /EvaluationEnzyme InhibitorsHuman SubjectHuman Therapy EvaluationMetalloendopeptidasesNeoplasm /Cancer ChemotherapySmall Cell Lung Cancer
Grant awards (6)
CNS PENETRATION STUDY$968
M01 · FY2005 · RR
NOVARTIS CGS27023A IN NON SMALL CELL LUNG CANCER PATIENTS$192,910
M01 · FY2002 · RR
NOVARTIS CGS27023A IN NON SMALL CELL LUNG CANCER PATIENTS$192,910
M01 · FY2001 · RR
NOVARTIS CGS27023A IN NON SMALL CELL LUNG CANCER PATIENTS$0
M01 · FY2001 · RR
NOVARTIS CGS27023A IN NON SMALL CELL LUNG CANCER PATIENTS$0
M01 · FY2000 · RR
NOVARTIS CGS27023A IN NON SMALL CELL LUNG CANCER PATIENTS$0
M01 · FY2000 · RR